U.S. Industrial REITs Stock News

NasdaqGS:MORN
NasdaqGS:MORNCapital Markets

Is It Time To Reassess Morningstar (MORN) After A 46% One Year Share Price Slide

If you are wondering whether Morningstar stock now offers value after a rough patch, starting with a clear look at price versus fundamentals can help frame your next move. The stock closed at US$166.05, with the share price declining 6.7% over the past week, 3.6% over the past month, 21.1% year to date, and 46.0% over the past year, which can change how investors think about both risk and opportunity. Recent coverage has focused on how market sentiment toward Morningstar has shifted, as...
NYSE:SAM
NYSE:SAMBeverage

Has Boston Beer Company (SAM) Share Price Slide Created A Potential Opportunity For Investors

If you are wondering whether Boston Beer Company stock now offers value or just more volatility, the recent share price moves give you plenty to think about. The stock is currently at US$173.18, with the share price down 14.7% over the past week, down 26.7% over the past month, and down 13.3% year to date. This may signal changing views on its potential and risk. Over a longer horizon, the share price has fallen 29.5% over the past year, 46.9% over three years and 83.5% over five years. This...
NYSE:BKV
NYSE:BKVOil and Gas

How BKV’s Q1 2026 Earnings Rebound and Output Surge Will Impact BKV (BKV) Investors

BKV Corporation recently reported past first-quarter 2026 results, with sales of US$71.29 million, revenue of US$432.85 million and net income of US$44.08 million, alongside higher production of 83,253 MMcfe versus 68,503 MMcfe a year earlier. The shift from a net loss and loss per share a year ago to positive earnings, combined with new production guidance of 925–975 MMcfe/d for the second quarter of 2026, highlights a sharp improvement in operating performance and management’s confidence...
NasdaqGS:TENB
NasdaqGS:TENBSoftware

Tenable Awards Key Partners As Tenable One Ecosystem Shapes Growth Story

Tenable Holdings honored its top global partners at the AssureWorld conference, recognizing Deloitte, Atos, and eSentire. The awards highlight partner contributions to expanding the Tenable One Exposure Management Platform. The event focused on advancing preemptive security adoption across Tenable's global customer base. Tenable Holdings (NasdaqGS:TENB) is putting its partner ecosystem front and center, using this year's AssureWorld conference to spotlight firms that are helping scale the...
NasdaqGM:AQST
NasdaqGM:AQSTPharmaceuticals

Aquestive Therapeutics (AQST) Q1 Loss Per Share Narrows Challenging Bearish Narratives

Aquestive Therapeutics (AQST) opened Q1 2026 with revenue of US$14.4 million and a reported loss of US$8.1 million, equal to a basic EPS loss of US$0.07. The trailing twelve months show revenue of US$50.3 million and a net loss of US$68.9 million or EPS of US$0.61. Over recent quarters the company has reported revenue rising from US$8.7 million in Q1 2025 to US$14.4 million in Q1 2026, with quarterly EPS losses ranging from US$0.24 to US$0.26 through 2025 before narrowing to US$0.07 in the...
NYSE:CRC
NYSE:CRCOil and Gas

How CRC’s Dividend, Losses and Carbon Capture Push Will Impact California Resources (CRC) Investors

In the first quarter of 2026, California Resources Corporation reported revenue of US$119 million versus US$912 million a year earlier, swinging from net income of US$115 million to a net loss of US$711 million, yet its board still declared a quarterly dividend of US$0.405 per share payable in June. Despite the sharp year-on-year earnings deterioration, the company raised full-year 2026 production guidance and highlighted progress on its carbon capture and storage project at the Elk Hills...
NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix (CRMD) Q1 Earnings Margin Surge Tests Bearish Narratives

CorMedix (CRMD) has opened 2026 with Q1 revenue of US$127.4 million and basic EPS of US$0.49, set against a very large year over year earnings expansion and a move in net profit margin from 20.8% to 45% over the past 12 months. The company has seen quarterly revenue step up from US$39.1 million in Q1 2025 to US$127.4 million in Q1 2026. Trailing twelve month EPS has moved from US$0.28 at the start of 2025 to US$2.38 by Q1 2026. This gives investors a results set where wider margins and higher...
NasdaqGM:ENPH
NasdaqGM:ENPHSemiconductor

Has The Recent Rebound Left Enphase Energy (ENPH) Trading Ahead Of Its Fundamentals

Wondering whether Enphase Energy's share price reflects its true worth, or if the recent moves have left it mispriced. The stock closed at US$48.01 after a sharp rebound, with returns of 35.4% over the past week, 50.0% over the past month and 42.3% year to date, even though the 1 year, 3 year and 5 year returns are down 3.4%, 70.7% and 66.1% respectively. Recent coverage has focused on how Enphase Energy fits into the broader semiconductor and clean energy story, with investors reacting to...
NYSE:BLK
NYSE:BLKCapital Markets

Is It Too Late To Consider BlackRock (BLK) After Strong Multi‑Year Share Gains?

For investors wondering whether BlackRock, at around US$1,104 per share, represents value or simply a premium price tag, this article outlines what the current data can and cannot indicate about that question. The stock has delivered returns of 3.4% over the past week, 4.7% over the past month, 1.7% year to date and 14.6% over the past year, with 3 year and 5 year returns of 77.0% and 47.3% respectively. These figures naturally raise questions about how much potential future upside or...
NYSE:GNL
NYSE:GNLREITs

Is Global Net Lease (GNL) Offering Value After A 26% One Year Share Price Rise

Wondering whether Global Net Lease at about US$9.20 is offering fair value or an opportunity? This article walks through what the current price may be implying. The stock is up 0.9% over the last week, has slipped 3.1% over the last month, yet sits 4.3% higher year to date and 26.3% higher over the past year. These moves can change how you think about both upside and risk. Recent headlines have focused on Global Net Lease as part of broader discussions around US listed real estate investment...
NasdaqGM:FATE
NasdaqGM:FATEBiotechs

Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation

Fate Therapeutics (FATE) opened 2026 with Q1 results showing revenue of about US$1.3 million and a basic EPS loss of US$0.26, alongside a net loss of US$31.2 million. Over recent quarters the company has seen quarterly revenue sit in a tight band around US$1.3 million to US$1.9 million, while basic EPS losses have moved between roughly US$0.26 and US$0.44 and trailing twelve month EPS has been around a US$1.09 loss. With the stock trading near US$1.90, the key question for investors is...
NYSE:AVA
NYSE:AVAIntegrated Utilities

Assessing Avista (AVA) Valuation As New Microgrid Project Highlights Its Energy Resilience Focus

Avista (AVA) is drawing fresh attention after Avista Utilities started operating a community-based microgrid at Spokane’s Dr. Martin Luther King Jr. Family Outreach Center. The project combines solar, battery storage, and natural gas to support energy resilience. See our latest analysis for Avista. At a share price of $41.16, Avista has delivered a 6.30% year to date share price return, while the 1 year total shareholder return of 11.34% suggests interest has been building around its recent...
NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Enovix (ENVX) TTM Loss Of US$171 Million Tests Bullish Growth Narratives

Enovix (ENVX) opened Q1 2026 with revenue of US$7.6 million and a basic EPS loss of US$0.18, alongside a net loss of US$38.26 million. On a trailing 12 month basis, the company generated US$34.32 million of revenue and a basic EPS loss of US$0.81 tied to a US$171.49 million net loss. Over recent quarters, the company has seen revenue range from US$5.10 million to US$11.27 million with quarterly basic EPS losses between US$0.12 and US$0.26. This provides a clear view of how growth and losses...
NasdaqGS:AKAM
NasdaqGS:AKAMIT

Akamai LayerX Acquisition Puts AI Browser Security And Valuation In Focus

Akamai Technologies (NasdaqGS:AKAM) has agreed to acquire LayerX, a provider of browser-based AI usage control and secure enterprise browser technology. The deal extends Akamai’s Zero Trust portfolio into browser-level protection for generative AI applications used inside enterprises. The acquisition targets growing enterprise concerns around how employees access and use AI tools through their web browsers. Akamai Technologies, trading at $155.67, has seen strong recent share price...
NYSE:BLSH
NYSE:BLSHCapital Markets

Bullish (BLSH) Q1 Loss Of US$581.7 Million Tests Growth Focused Narratives

Bullish (BLSH) opened 2026 with Q1 revenue of US$77.5 million, a basic EPS loss of US$3.85, and a net loss of US$581.7 million, setting a tough but clear baseline for investors watching how the story develops from here. Over the past year, the company has seen quarterly revenue move from US$39.3 million in Q4 2024 to US$77.5 million in Q1 2026, while EPS has swung between a profit of US$1.39 and losses such as US$3.85, highlighting how quickly margins can shift as the business scales. With...
NasdaqGM:BRCB
NasdaqGM:BRCBHospitality

Black Rock Coffee Bar (BRCB) Margins Edge Into Profit Challenges Cautious Earnings Narratives

Black Rock Coffee Bar (BRCB) opened Q1 2026 with revenue of US$55.5 million and basic EPS of US$0.02, alongside net income of US$0.4 million. These results put fresh numbers behind a company that has recently moved into profitability on a trailing twelve month basis. The company has seen quarterly revenue move from US$42.8 million in Q4 2024 to US$51.5 million in Q3 2025 and then US$53.6 million in Q4 2025. Trailing twelve month EPS shifted from a loss of US$0.33 in Q2 2025 to a small profit...
NasdaqGS:RGNX
NasdaqGS:RGNXBiotechs

Regenxbio (RGNX) Q1 Loss Deepens And Reinforces Bearish Cash Runway Concerns

REGENXBIO (RGNX) Q1 2026 earnings snapshot REGENXBIO (RGNX) has just posted Q1 2026 results with revenue of US$6.4 million and a basic EPS loss of US$1.72, against a trailing twelve month basic EPS loss of US$5.59 on revenue of US$87.8 million. Over recent quarters the company has reported revenue of US$89.0 million in Q1 2025, followed by US$21.4 million in Q4 2024. Basic EPS moved from a profit of US$0.12 in Q1 2025 to a loss of US$1.01 in Q4 2024. These figures are likely to draw investor...
NYSE:LEG
NYSE:LEGConsumer Durables

Leggett & Platt (LEG) Is Down 8.0% After Q1 2026 Sales and Profit Decline - What's Changed

Leggett & Platt, Incorporated has reported past first-quarter 2026 results showing sales of US$918.2 million, down from US$1,022.1 million a year earlier, with net income falling from US$30.6 million to US$20 million. The simultaneous decline in both revenue and profitability gives investors a fresh data point on how the company is managing current demand conditions and cost pressures. We’ll now examine how this quarter’s weaker sales and earnings reshape Leggett & Platt’s investment...
NasdaqGS:NBIS
NasdaqGS:NBISSoftware

Nebius Group (NBIS) Q1 Profitability Surge Tests Justification For Rich 77x P/E

Nebius Group (NasdaqGS:NBIS) has opened 2026 with Q1 revenue of US$399 million and Basic EPS of US$2.40, alongside net income of US$621.2 million, setting a clear marker after a volatile run of prior quarters. The company has seen revenue move from US$55.3 million in Q1 2025 and US$35.2 million in Q4 2024 to US$399 million in Q1 2026, with Basic EPS shifting from a loss of US$0.48 in Q1 2025 and a loss of US$0.58 in Q4 2024 to a profit of US$2.40. This puts the focus firmly on how sustainable...
NasdaqGS:COO
NasdaqGS:COOMedical Equipment

New Cooper Companies Director Adds Oversight As Shares Trade Below Targets

Cooper Companies (NasdaqGS:COO) has appointed Paul Keel to its Board of Directors. Keel will also serve on the Board’s Audit Committee. The appointment brings experience from senior executive roles at major medical technology and industrial companies. For investors watching Cooper Companies at a share price of $60.38, this board change comes after a period of weak stock performance. The stock is down 15.7% over the past 30 days, 25.6% year to date, and 25.9% over the past year, with a 37.9%...
NasdaqCM:SSII
NasdaqCM:SSIIMedical Equipment

SS Innovations International (SSII) Losses Challenge Bullish Narratives After Q1 2026 Results

SS Innovations International (NasdaqCM:SSII) opened 2026 with Q1 revenue of about US$11.1 million and a basic EPS loss of US$0.02, while trailing 12 month figures show revenue of roughly US$48.5 million and a basic EPS loss of US$0.05. Over the past reported quarters, revenue has ranged from about US$5.1 million in Q1 2025 to US$14.5 million in Q4 2025, with basic EPS losses moving between roughly US$0.00 and US$0.03 per share. Investors are therefore likely to focus on how efficiently that...
NYSE:BHVN
NYSE:BHVNBiotechs

Biohaven (BHVN) Narrows Loss and Adds Shelf Registration Is Its Capital Strategy Evolving?

Biohaven Ltd. reported first-quarter 2026 results in the past, narrowing its net loss to US$130.53 million from US$221.68 million a year earlier, while loss per share from continuing operations declined to US$0.88 from US$2.17. On the same day, Biohaven filed an omnibus shelf registration covering a wide range of securities, potentially giving the company considerable flexibility in how it may access capital in the future. With these earnings and the broad shelf registration in mind, we’ll...
NYSE:RAMP
NYSE:RAMPSoftware

Valpak Data Integration Could Be A Game Changer For LiveRamp Holdings (RAMP)

In May 2026, Valpak Intelligence announced that its New Mover and New Business audience segments became directly available in LiveRamp’s Data Marketplace, giving marketers, brands, and agencies streamlined access to its postal-anchored identity data across major DSPs, SSPs, CTV platforms, and CRM destinations without separate licensing agreements. This partnership brings Valpak’s decades-built household identity spine, spanning approximately 135 million households and hundreds of millions of...
NasdaqGM:KROS
NasdaqGM:KROSBiotechs

Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives

Keros Therapeutics (KROS) has just posted Q1 2026 results, with revenue of US$0.4 million, a basic EPS loss of US$1.21 and a net loss of US$23.7 million, setting the tone for the quarter at a share price of US$10.99. The company has seen quarterly revenue move from US$211.2 million in Q1 2025 to US$0.4 million in Q1 2026, while basic EPS shifted from a profit of US$3.66 to a loss of US$1.21. This puts the spotlight on how changes in revenue expectations and potential margin developments could...